Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

González Martín, A; Oza, A; Embleton, AC; Pfisterer, J; Ledermann, J; Pujade-Lauraine, E; Kristensen, G; ... Perren, T; + view all González Martín, A; Oza, A; Embleton, AC; Pfisterer, J; Ledermann, J; Pujade-Lauraine, E; Kristensen, G; Bertrand, M; Beale, P; Cervantes, A; Kent, E; Kaplan, R; Parmar, M; Scotto, N; Perren, T; - view fewer (2018) Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology 10.1016/j.ygyno.2018.08.036 . (In press). Green open access

https://ift.tt/2PDAd3e